Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Equity (2019 - 2025)

Keros Therapeutics filings provide 7 years of Return on Equity readings, the most recent being 0.0% for Q4 2025.

  • On a quarterly basis, Return on Equity rose 1.0% to 0.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.0%, a 1.0% increase, with the full-year FY2025 number at 0.0%, up 1.0% from a year prior.
  • Return on Equity hit 0.0% in Q4 2025 for Keros Therapeutics, up from 0.0% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.0% in Q4 2025 to a low of 0.01% in Q4 2023.
  • Median Return on Equity over the past 5 years was 0.0% (2022), compared with a mean of 0.0%.
  • Biggest five-year swings in Return on Equity: decreased -1bps in 2021 and later rose 1bps in 2025.
  • Keros Therapeutics' Return on Equity stood at 0.0% in 2021, then tumbled by -59bps to 0.0% in 2022, then crashed by -34bps to 0.01% in 2023, then skyrocketed by 37bps to 0.0% in 2024, then soared by 151bps to 0.0% in 2025.
  • The last three reported values for Return on Equity were 0.0% (Q4 2025), 0.0% (Q3 2025), and 0.0% (Q2 2025) per Business Quant data.